

## Defibrotide

Reference Number: F4805 Date of Response: 12/09/2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

## Royal Devon's Eastern FOI Office Response

Number of patients with a diagnosis of Hepatic Veno-Occlusive Disease (ICD-10 K765) and their age at the time of treatment in the following time periods:

	Apr- 20	May- 20	Jun- 20	Jul- 20	Aug- 20	Sep- 20	Oct- 20	Nov- 20	Dec- 20	Jan- 21	Feb- 21	Mar- 21
Adult (aged 18+)	0	0	0	0	0	0	0	0	0	0	0	0
Child (aged 17 or under)	0	0	0	0	0	0	0	0	0	0	0	0

How many Blueteq application forms were submitted (for reimbursement) for the use of defibrotide for the treatment of Severe Veno-Occlusive Disease (VOD) after stem cell transplant in the specified time periods below?) 0.

Blueteq applications submitted for the use of defibrotide for the treatment of Hepatic Veno Occlusive Disease (VOD) after stem cell transplant:

	Apr -20	May -20	Jun -20	Jul -20	Aug -20	Sep -20	Oct -20	Nov -20	Dec -20	Jan -21	Feb -21	Mar -21
Adult (aged 18+)	0	0	0	0	0	0	0	0	0	0	0	0
Child (aged 17 or under)	0	0	0	0	0	0	0	0	0	0	0	0



Number of patients diagnosed with VOD split by age and by transplant type in the following time periods:

		Apr- 20	May- 20	Jun- 20	Jul- 20	Aug- 20	Sep- 20	Oct- 20	Nov- 20	Dec- 20	Jan- 21	Feb- 21	Mar- 21
Autologous	Adult 18+	0	0	0	0	0	0	0	0	0	0	0	0
	Child (17 or under)	0	0	0	0	0	0	0	0	0	0	0	0
Allogeneic	Adult 18+	0	0	0	0	0	0	0	0	0	0	0	0
	Child (17 or under)	0	0	0	0	0	0	0	0	0	0	0	0